viewSilence Therapeutics PLC

Silence Therapeutics says Iain Ross to return as its chairman and non-executive director with immediate effect

Ross was Silence's chairman from 2005 to 2010 and is currently is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma PLC

Silence also announced the appointment of James Ede-Golightly as a non-executive director, and said Stephen Parker will step down from that role

Silence Therapeutics PLC (LON:SLN) shares rose on Thursday following news it has appointed Iain Ross as a non-executive director and its chairman with immediate effect, with the experienced director returning to a role he held from 2005 to 2010.

The AIM-listed group, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, pointed out that Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years.

READ: Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

Currently, it added, he is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma Plc.

Dr. David Horn Solomon, Silence’s chief executive officer commented: “Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers.”

Incoming chairman Ross added: "I am delighted to be returning to Silence Therapeutics and I look forward to working with David, the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the Board to deliver on its potential."

Silence also announced the appointment of James Ede-Golightly as a non-executive director, while it said Stephen Parker will step down from that role, both with immediate effect.

Ede-Golightly is currently chairman of DeepMatter Group PLC and Oxford Advanced Surfaces Ltd and a non-executive director at Oxehealth Limited.

In a note to clients, analysts at ‘house’ broker Peel Hunt pointed out that  today’s announcements follow other recent changes to Silence’s management and the board. 

“As a reminder of other recent appointments at Silence, Rob Quinn was appointed CFO from his role as interim CFO (18th April) and Giles Campion was appointed (16th April) Head of R&D and Chief Medical Officer (previously SVP of R&D at Prosena and holding senior roles at Novartis and Albumedix),” they said.

Peel Hunt continues to have its rating and target price for Silence ‘under review’.

In afternoon trading, the shares were 4.3% higher at 73p.

 -- Adds analyst comment, share price -- 

Quick facts: Silence Therapeutics PLC

Price: 184 GBX

Market: AIM
Market Cap: £144.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

2 weeks, 3 days ago

2 min read